JP2021530525A5 - - Google Patents

Info

Publication number
JP2021530525A5
JP2021530525A5 JP2021502574A JP2021502574A JP2021530525A5 JP 2021530525 A5 JP2021530525 A5 JP 2021530525A5 JP 2021502574 A JP2021502574 A JP 2021502574A JP 2021502574 A JP2021502574 A JP 2021502574A JP 2021530525 A5 JP2021530525 A5 JP 2021530525A5
Authority
JP
Japan
Prior art keywords
oxazepan
carboxamide
ethyl
cyano
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042021 external-priority patent/WO2020018547A1/en
Publication of JP2021530525A publication Critical patent/JP2021530525A/ja
Publication of JP2021530525A5 publication Critical patent/JP2021530525A5/ja
Pending legal-status Critical Current

Links

JP2021502574A 2018-07-17 2019-07-16 ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド Pending JP2021530525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699494P 2018-07-17 2018-07-17
US62/699,494 2018-07-17
PCT/US2019/042021 WO2020018547A1 (en) 2018-07-17 2019-07-16 Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Publications (2)

Publication Number Publication Date
JP2021530525A JP2021530525A (ja) 2021-11-11
JP2021530525A5 true JP2021530525A5 (cg-RX-API-DMAC7.html) 2022-07-20

Family

ID=69164738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502574A Pending JP2021530525A (ja) 2018-07-17 2019-07-16 ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド

Country Status (7)

Country Link
US (1) US11998553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823627A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530525A (cg-RX-API-DMAC7.html)
KR (1) KR20210032431A (cg-RX-API-DMAC7.html)
AU (1) AU2019306532A1 (cg-RX-API-DMAC7.html)
CA (1) CA3106269A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020018547A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物
TW202404960A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并[c]色滿化合物的多晶型及其製備方法和用途
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DE60131423T2 (de) 2000-09-08 2009-03-19 Prozymex A/S Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
PL370766A1 (en) 2001-12-04 2005-05-30 F.Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004106289A1 (en) 2003-05-30 2004-12-09 Prozymex A/S Protease inhibitors
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
EP1745292A2 (en) * 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
BRPI0508063A (pt) 2004-06-29 2007-07-17 Nycomed Danmark Aps processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
JP5704785B2 (ja) 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのflt3阻害剤
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
KR20100060004A (ko) 2007-09-25 2010-06-04 노파르티스 아게 에어로졸화된 반코마이신과 같은 의약에 의한 폐 질병의 치료
US7902181B2 (en) 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
PT2413913T (pt) 2009-04-01 2022-06-09 Bial Portela & Ca Sa Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
EA201190235A1 (ru) 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
JP6479476B2 (ja) 2012-02-21 2019-03-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung SykチロシンキナーゼインヒビターおよびGCN2セリンキナーゼインヒビターとしての8−置換2−アミノー[1,2,4]トリアゾロ[1,5−A]ピラジン類
CA2870527A1 (en) 2012-04-17 2013-10-24 Astellas Pharma Inc. Nitrogenated bicyclic aromatic heterocyclic compound
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
EP2970252B1 (en) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンcの置換二環式1−カルボン酸(ベンジル−シアノ−メチル)−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
CN105612149A (zh) 2013-09-09 2016-05-25 普罗技迈克斯公司 作为二肽基肽酶i抑制剂的肽基腈化合物
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN106456552A (zh) 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
CN107075557B (zh) 2014-05-30 2021-07-06 香港大学 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
MX370366B (es) 2014-11-14 2019-12-11 Boehringer Ingelheim Int Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4).
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2018022978A1 (en) 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
WO2020018551A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
EP4252844A3 (en) 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20240226112A1 (en) 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN118159525A (zh) 2021-10-29 2024-06-07 英斯梅德股份有限公司 用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
JP2025508359A (ja) 2022-02-16 2025-03-26 インスメッド インコーポレイテッド 化膿性汗腺炎を治療するためのある特定のn-(1-シアノ-2-フェニルエチル)-1,4-オキサゼパン-2-カルボキサミド

Similar Documents

Publication Publication Date Title
JP2021512904A5 (cg-RX-API-DMAC7.html)
JP2023156479A5 (cg-RX-API-DMAC7.html)
JP2021530513A5 (cg-RX-API-DMAC7.html)
JP2022096662A5 (cg-RX-API-DMAC7.html)
US6436938B1 (en) Combination treatment for depression
TW202327569A (zh) 包含tead抑制劑的藥物組合及其用於癌症治療之用途
JP2022166188A5 (cg-RX-API-DMAC7.html)
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
CN1155409C (zh) 用于预防和治疗动脉硬化的药物组合物
US20020123490A1 (en) Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
JPWO2006022428A1 (ja) 糖尿病治療剤
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2024516826A5 (cg-RX-API-DMAC7.html)
JP2005526696A5 (cg-RX-API-DMAC7.html)
US20020107244A1 (en) Combination treatment for depression
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
JP2021522270A5 (cg-RX-API-DMAC7.html)
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
JP2021530525A (ja) ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド
WO2019151470A1 (ja) 眼内血管新生及び/又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬
JP2005532397A5 (cg-RX-API-DMAC7.html)
MXPA02005380A (es) Tratamiento de combinacion para trastornos del sueno, incluyendo la apnea del sueno.
JP2015510893A (ja) 精神障害の治療における使用のためのイロペリドン代謝物